Intervertebral DXM Gel Injection in Adults With Painful Lumbar Degenerative Disc Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-15

Study Completion Date

2021-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the safety and the efficacy of an hydrogel (double cross-link microgel - DXM) injection into the intervertebral disc (IVD) space in patients with painful lumbar degenerative disc disease (DDD) over 24 to 48 weeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

RCT Study of the Gelstix™ Device to Treat Chronic Discogenic Low Back Pain GelStix Study

NCT02763956

Degeneration of Lumbar Intervertebral Disc

RECRUITING NA

Efficacy of Intradiscal Injection of BM-MSC in Subjects With Chronic Low Back Pain (LBP) Due to Lumbar Degenerative Disc Disease (DDD) Unresponsive

NCT03737461

Recurrent Low Back Pain Degenerative Disc Disease (DDD)

ACTIVE_NOT_RECRUITING PHASE2/PHASE3

Study of the Safety and Effectiveness of DIAM™ Spinal Stabilization System Versus Conservative Care

NCT00456378

Lumbar Degenerative Disc Disease

TERMINATED NA

Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain

NCT02412735

Degenerative Disc Disease

COMPLETED PHASE3

Mesenchymal Stem Cells for Lumbar Degenerative Disc Disease

NCT03692221

Disc Degeneration

WITHDRAWN EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After being informed of the study and the potential risks, all patients matching the eligibility criteria and who have given their written consent will undergo a gel injection at day 0 after a period of screening of up to 14 days.

Then, they will be followed-up for a variable period according to the cohort :

* first cohort of 5 patients with only one disc to be treated will be followed during 48 weeks,
* second cohort of 5 patients with 2 discs to be treated will be followed during 36 weeks,
* third cohort of 10 patients with 1 or 2 discs to be treated will be followed during 24 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Degenerative Disc Disease Chronic Lower Back Pain Discogenic Pain Intervertebral Disc Degeneration Lumbar Disc Disease Lumbar Disc Degeneration Lumbar Disc Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This is an adaptative-design, interventional, open-label, single-arm trial performed at a single centre in France.

3 cohorts will be sequentially initiated according to the DSMB review of the safety parameters :

The safety primary endpoints of each cohort will be assessed by an independent Data Safety Monitoring Board (DSMB) at Day 42 post-injection to provide safety oversight on the patients and guidance on initiating the study on the next cohort.

Patients will be injected at day 0 and will be followed-up for a variable period according to the cohort.

* As the first enrolled cohort, the 1L cohort will have the longest follow-up (48 weeks) and will attend 9 visits.
* The second cohort (2L) will have a shorter follow-up period (36 weeks) attend the same visits except for V9, which will not be done.
* The third cohort (1-2L) will will have the shorter follow-up period (24 weeks) and will attend visits 1 to 7 except for V4, which will not be done.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

single-arm of 3 cohorts

These patients will be sequentially recruited in 3 cohorts :

* One disc level cohort: 5 patients with only one disc to be treated; First enrolled cohort with 48 weeks of follow-up (9 visits V1-V9)
* Two disc level cohort: 5 patients with 2 discs to be treated; Second enrolled cohort with 36 weeks of follow-up (8 visits, same visits except for V9)
* One or two disc level cohort: 10 patients with 1 or 2 discs to be treated; Third enrolled cohort with 24 weeks of follow-up (6 visits, V1 to 7 except for V4)

Group Type EXPERIMENTAL

Double Crosslink Microgel

Intervention Type DEVICE

DXM hydrogel is a pH responsive Double Cross-Linked microgel based on single internally cross-linked microspheres (comprising a methacrylic acid-methyl methacrylate-ethylene glycol dimethacrylate copolymer)

The DXM gel is injected into the intervertebral disc (IVD) space via a standardised procedure similar to the routinely-performed Discography procedure. The disc approach described in the discography procedure has been reported to allow the injection of a solution in the centre of the disc. The injection of the gel takes about 2 min.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Double Crosslink Microgel

DXM hydrogel is a pH responsive Double Cross-Linked microgel based on single internally cross-linked microspheres (comprising a methacrylic acid-methyl methacrylate-ethylene glycol dimethacrylate copolymer)

The DXM gel is injected into the intervertebral disc (IVD) space via a standardised procedure similar to the routinely-performed Discography procedure. The disc approach described in the discography procedure has been reported to allow the injection of a solution in the centre of the disc. The injection of the gel takes about 2 min.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

DXM gel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female patient aged between 18 and 55 (inclusive)
2. Discogenic low back pain, confirmed by a history of Low Back Pain, with a minimum of 3 months of continuous pain or 6 months of acute episodes of pain despite the conservative treatment including painkillers and physiotherapy
3. Oswestry Disability Index (ODI) ≥ 30% and ≤ 60%,
4. Painful disc(s) between L1 and S1 represented

1. For cohort 1L: at a single disc level
2. For cohort 2L: at 2 disc levels
3. For cohort 1-2L: at 1 or 2 disc levels
5. Patients with a Zung depression score ≤ 49, Note: Patients with a Zung depression score between ≥ 50 and ≤ 64 may be included if deemed suitable for trial inclusion by the investigator
6. Partial dehydration (grey disc) confirmed by MRI, grade II/III Pfirrmann classification

Note:
* Pfirrmann Grade IV and V disc lesions are absolute contra-indications for inclusion
7. Female patients of childbearing potential must have a negative urine pregnancy test at screening and use an effective birth control during the follow up period after the injection procedure
8. Patients who are willing and capable of understanding the investigator's explanations, following his instructions and adhering to the follow-up visits according to the study protocol, including a willingness and ability to undergo MRI scanning,
9. Patient giving informed consent to take part in the study

Exclusion Criteria

1. Averted nerve root pain and potential root compression Note: Referred leg pain authorised
2. Presence of posterior bone spurs (osteophytes)
3. Partial or total Modic signal grade 1 at the considered disc level
4. Patients with active systemic infection or infection localized to the site of the proposed implantation.
5. Any conditions not described in the indications for use.
6. Any mental conditions or neuromuscular disease that may generate an unacceptable risk of failure or postoperative complication.
7. Patients with existing disc herniation at the considered level and on adjacent discs
8. Endplate disease, defect or weakness, e.g. Schmorl nodule
9. Vertebral bone abnormalities with active angioma
10. Disc collapse ≥ 15% when disc height is compared to the height of the upper adjacent disc
11. One lumbar disc rated grade IV or V on the Pfirrmann classification
12. Imaging showing facet arthrosis
13. Lytic spondylolisthesis
14. Degenerative spondylolisthesis grade \> grade I Meyerding
15. Congenital or idiopathic deformities of the spine (e.g. Scoliosis \>20° Cobb or Kyphosis)
16. Old or acute vertebral fractures in the lumbar spine
17. Patients with any prior spine procedure in the lumbar spine
18. Any skin disease or inadequate tissue coverage at the site of the injection
19. Any medical or surgical conditions that could preclude the potential benefit of disc injection must be carefully analysed before the procedure, such as congenital abnormalities, immunosuppressive disease, elevation of erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) concentration not explained by other diseases, elevation of white blood cell (WBC) count, or marked left shift in the WBC differential count, should be carefully taken into consideration prior to the surgical procedure.

Note: These contra-indications can be relative or absolute and must be taken into account by the physician when making his decision. The above list is not exhaustive.
20. Tumours with any metastatic potential, or known metastases, in any part of the body
21. Known infection with HIV or Hepatitis B, C or E
22. Patient that has received or is seeking employee compensation
23. Zung depression score ≥ 65
24. Substance abuse or dependency (pharmaceuticals, drugs, alcohol)
25. Disabling obesity (BMI \> 35kg/m²)
26. History of chemical dependency (e.g. illicit drugs, or opiates) or significant emotional or psychosocial disturbance which may have an effect on treatment outcome
27. Patients who are pregnant, breast feeding or planning pregnancy during the study
28. Anticoagulation (beyond low level prophylactic doses of single anti-platelet agents)
29. Inability to undertake or known contra-indications to MRI scanning
30. Known hypersensitivity to barium sulphate

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No